Details for Patent: 7,674,479

Which drugs does patent 7,674,479 protect, and when does it expire?

Patent 7,674,479 protects FORFIVO XL and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 7,674,479

Title:	Sustained-release bupropion and bupropion/mecamylamine tablets
Abstract:	Sustained-release bupropion hydrochloride pharmaceutical tablets and combination sustained-release bupropion hydrochloride/mecamylamine hydrochloride pharmaceutical tablets are obtained by granulating the bupropion hydrochloride with a hydroxyalkylcelluose, and blending the resulting granules within an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which then is coated, with a means to provide delayed release, such as with an enteric coating composition. The mecamylamine hydrochloride can be contained in a second granule comprising a hydroxyalkylcellulose.
Inventor(s):	Horst G. Zerbe, Nadine Paiement
Assignee:	IntelGenx Corp
Application Number:	US11/828,287
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,674,479
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form;

Drugs Protected by US Patent 7,674,479

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Twi Pharms	FORFIVO XL	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022497-001	Nov 10, 2011		RX	Yes	Yes	7,674,479		Y

International Family Members for US Patent 7,674,479

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2008038155